WAVEMAN · COMPANY

VTRS · Viatris Inc

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

VTRS

Name: Viatris Inc (VTRS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Viatris Inc

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001792044

CONGRESS · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$1.1M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

485

13F, latest reported quarter

REVENUE GROWTH

-3.0%

XBRL, annual

NET MARGIN

-24.7%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$1.1M over 180 days

-$809.7K over 90 days

below 61% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

485 funds added or opened last quarter

more than 96% of Pharma & Biotech

REVENUE

-3.0% year over year

below 62% of Pharma & Biotech

MARGIN

-24.7% net margin

below 52% of Pharma & Biotech

BUYBACKS

$150.0M repurchased, FY to 2026-06-30

more than 71% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

485 funds added or opened positions in the latest 13F quarter, of 1,032 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +64.3%

+64.3%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $1.1M sold by insiders over 180 days, 485 funds added last quarter, 1 Congress member(s) bought in 12 months, $809.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Viatris Inc insiders sold a net $1.1M of stock across 48 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Campbell Paul

See Remarks

SELL

2026-06-25

50,076.0

$809.7K

Campbell Paul

See Remarks

SELL

2026-03-23

21,350.0

$283.5K

SIMMONS DAVID S

Director

BUY

2025-11-03

213.0

$2.2K

Le Goff Corinne

Chief Commercial Officer

SELL

2025-09-11

7,032.0

$72.1K

SIMMONS DAVID S

Director

BUY

2025-08-27

286.0

$3.0K

48 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 43 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

96,662,102.0 sh

$1.5B

BlackRock, Inc.

86,019,468.0 sh

$1.4B

VANGUARD CAPITAL MANAGEMENT LLC

76,046,939.0 sh

$1.2B

Davis Selected Advisers

75,232,254.0 sh

$1.2B

VANGUARD PORTFOLIO MANAGEMENT LLC

54,282,080.0 sh

$862.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Paul Campbell

FILED 2026-06-25

$809.7K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Callodine Equity Income Series

$17.1M POSITION · AS OF 2026-03-31

7.9%

Davis Opportunity Fund

$36.0M POSITION · AS OF 2026-03-31

6.1%

Davis Select U.S. Equity ETF

$57.6M POSITION · AS OF 2026-04-30

5.0%

Davis Balanced Fund

$14.3M POSITION · AS OF 2026-03-31

4.9%

Miller Income Fund

$8.4M POSITION · AS OF 2026-03-31

4.9%

Davis Global Fund

$43.9M POSITION · AS OF 2026-04-30

4.8%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 5 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 4

2 ACTIVE

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Viatris Inc. Political Action Committee (Viapac)

CYCLE 2026 · $222K SPENT

$258.9K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$14.3B	$14.7B	$15.4B	$16.2B
GROSS PROFIT	$5.0B	$5.6B	$6.4B	$6.5B
OPERATING INCOME	$-2.7B	$10.1M	$766.2M	$1.6B
NET INCOME	$-3.5B	$-634.2M	$54.7M	$2.1B
EPS (DILUTED)	-3.00	-0.53	0.05	1.71
OPERATING CASH FLOW	$2.3B	$2.3B	$2.9B	$3.0B
CASH	$1.3B	$734.8M	$991.9M	$1.3B
LONG-TERM DEBT	$12.5B	$14.0B	$16.2B	$18.0B
BUYBACKS	$500.5M	$250.0M	$250.0M	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE